Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evoke Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EVOK
Nasdaq
2834
https://evokepharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evoke Pharma Inc
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
- Apr 17th, 2024 12:30 pm
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
- Mar 21st, 2024 8:15 pm
Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?
- Mar 16th, 2024 2:14 pm
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript
- Mar 15th, 2024 5:58 pm
Q4 2023 Evoke Pharma Inc Earnings Call
- Mar 15th, 2024 10:56 am
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 14th, 2024 8:05 pm
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
- Mar 7th, 2024 9:10 pm
Evoke Pharma Announces Closing of $7.5 Million Public Offering
- Feb 14th, 2024 12:30 pm
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
- Feb 9th, 2024 12:30 pm
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray
- Nov 30th, 2023 5:16 pm
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
- Nov 27th, 2023 1:30 pm
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
- Nov 14th, 2023 1:30 pm
Evoke Pharma Reports Third Quarter 2023 Financial Results
- Nov 9th, 2023 1:30 pm
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
- Oct 31st, 2023 12:30 pm
7 Under-the-Radar Growth Stocks Ready to Make a Splash
- Oct 23rd, 2023 10:30 am
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting
- Oct 18th, 2023 12:30 pm
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
- Sep 14th, 2023 12:30 pm
Evoke Pharma Reports Second Quarter 2023 Financial Results
- Aug 10th, 2023 12:30 pm
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
- Aug 7th, 2023 12:30 pm
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
- Jul 25th, 2023 12:30 pm
Scroll